A211000

DMT-2′O-TBDMS-rA(bz) Phosphoramidite

• Synonim(y): DMT-2’O-TBDMS-rA(bz) Amidite, N-benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-O-[(1,1-dimethylethyl)dimethylsilyl]-adenosine, 3′-[2-cyanoethyl N,N-bis(1-methylethyl)phosphoramidite]
• Wzór empiryczny (zapis Hilla): C₅₃H₆₆N₇O₈PSi
• Numer CAS: 104992-55-4
• Masa cząsteczkowa: 988.19
• NACRES: NA.51
• PubChem Substance ID: 329770730
• UNSPSC Code: 12352200
• MDL number: MFCD00080297
• Assay: ≥99% (³¹P-NMR), ≥99.0% (reversed phase HPLC)
• Biological source: non-animal source (no BSE/TSE risk)
• Form: powder
• Storage temp.: −20°C

Właściwości

• biological source: non-animal source (no BSE/TSE risk)
• Quality Segment: 200, 300
• product line: Proligo Reagents
• assay: ≥99% (³¹P-NMR), ≥99.0% (reversed phase HPLC)
• form: powder
• technique(s): oligo synthesis: suitable
• impurities: ≤0.3 wt. % water content (Karl Fischer), ≤0.5% P(III) Impurities 100-169ppm (³¹P-NMR), ≤0.5% single Impurity (reversed phase HPLC), ≤3 wt. % residual Solvent content
• color: white to off-white
• λ: conforms (UV/VIS Identity)
• suitability: conforms to structure for H-NMR, conforms to structure for LC-MS
• nucleoside profile: base: adenosine; base protecting group: benzoyl; 2' protecting group: TBDMS; 5' protecting group: DMT; deprotection: standard
• storage temp.: −20°C
• SMILES string: COc1ccc(cc1)C(OC[C@H]2O[C@H]([C@H](O[Si](C)(C)C(C)(C)C)[C@@H]2OP(OCCC#N)N(C(C)C)C(C)C)n3cnc4c(NC(=O)c5ccccc5)ncnc34)(c6ccccc6)c7ccc(OC)cc7
• InChI: 1S/C53H66N7O8PSi/c1-36(2)60(37(3)4)69(65-32-18-31-54)67-46-44(33-64-53(39-21-16-13-17-22-39,40-23-27-42(62-8)28-24-40)41-25-29-43(63-9)30-26-41)66-51(47(46)68-70(10,11)52(5,6)7)59-35-57-45-48(55-34-56-49(45)59)58-50(61)38-19-14-12-15-20-38/h12-17,19-30,34-37,44,46-47,51H,18,32-33H2,1-11H3,(H,55,56,58,61)/t44-,46-,47-,51-,69?/m1/s1
• InChI key: FFXHNCNNHASXCT-RFMFGJHUSA-N

Opis

General description

DMT-2′O-TBDMS-rA(bz) Phosphoramidite belongs to the group of 2′O-TBDMS RNA Phosphoramidites.

Application

RNA interference (RNAi) has become a popular tool for the sequence-specific inhibition of gene expression and can be used in target validation and other drug development techniques. The most convenient method to provide sequence-specific RNA oligonucleotides is a chemical synthesis on a solid support with RNA phosphoramidites and RNA CPG, analogous to DNA synthesis.

Features and Benefits

• Industry standard 2′O-TBDMS protective group
• Consistent lot-to-lot purity and performance
• Compatible with deprotection methods based on methylamine or AMA
• Standard RNA phosphoramidites provide excellent coupling results when used with ETT or BTT as activator; best results are obtained with Activator 42
• Capping with standard acetic anhydride capping reagent rather than with Fast Deprotection Cap A
• Manufactured under a certified ISO 9001 quality system

Other Notes

The unique properties of RNA have stimulated the development of a variety of applications in diagnostics and therapeutics, as well as in basic molecular biology research where RNA can be used as:

• Catalytic agents (ribozymes)
• Affinity ligands (aptamers)
• Agents to induce gene silencing (RNA interference)

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable